Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is that the reason no PR because he is on vacation?
Very quiet for the last month and this month! What's going on?
Best place to have fun and play in New Jersey! Bunch idiots running the company!
Amgen already have Oncolytic Immunotherapy Virus, why need LM?
I was thinking about this too. No deal with Medimmune, no deal with Amgen, no deal with AStra, only one left is Merck
KEN and BOD still in shock, dont' know what to do at this moment.
Why no PR today?
Lets merge with Aduro, perfect match
I dont believe this reason either
Company is only worth $20million MC. I guess the science is worthless for Amgen! we all got fxxked!
Now you know why no insiders buying stocks!!!!
Then Amgen should buy the whole company!
Just two days ago Robert G. Petit wrote on linkedin he is exciting to see
Exactly what our vectors generate going after neoantigens in the tumor cells. I love seeing these cells in action!
Could be or the science just sucks! Also could be the reason J&J terminated with Aduro!
very bad luck invested with this company!
AMGEN terminated ADXS-NEO with ADVAXIS!!!!!!!!! 8-K filed
https://www.sec.gov/Archives/edgar/data/1100397/000149315218017447/form8-k.htm
On December 10, 2018, Advaxis, Inc., a Delaware Corporation (the “Company”) received a written notice of termination from Amgen Inc. (“Amgen”) with respect to the License and Collaboration Agreement, dated as of August 1, 2016 (the “Amgen Agreement”) pertaining to the development and commercialization of the Company’s ADXS-NEO program, a novel, preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector, which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. The termination is effective as of February 8, 2019. The Company’s ADXS-NEO study is currently enrolling patients and the Company will evaluate whether to re-partner the ADXS-NEO program.
Under the terms of the Amgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize the ADXS-NEO program. Amgen previously made an upfront payment to the Company of $40 million, purchased $25 million of the Company’s common stock and reimbursed the Company for certain research and development costs in support of the ADXS-NEO program. Under the Amgen Agreement, the Company and Amgen collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. The Company was eligible to receive future contingent payments based on development, regulatory and sales milestones as well as high single digit to double digit royalty payments based on worldwide sales of licensed products by Amgen. Pursuant to the terms of the Amgen Agreement, upon Amgen’s termination, the license to Amgen will terminate and the Company will regain worldwide rights for the development and commercialization of its ADXS-NEO program. In addition, Amgen will have certain obligations as set forth in the Amgen Agreement, including promptly deleting or destroying any materials related to the development or manufacturing of the ADXS-NEO program. During the fiscal years ended October 31, 2018 (unaudited) and 2017, the Company recorded reimbursements of approximately $5.8 million and $7.5 million, respectively, relating to the Amgen Agreement
The foregoing description of the Amgen Agreement does not purport to be complete and is qualified in its entirety by the full text of the Amgen Agreement, which has been previously filed as Exhibit 10.57 to the Company’s Annual report on Form 10-K, filed with the Securities and Exchange Commission on January 9, 2017.
three Michelin stars with some Listeria ingredient, sounds great!
I like what Dr. Robert Petit said on linkedin yesterday:
Exactly what our vectors generate going after neoantigens in the tumor cells. I love seeing these cells in action!
check linkedin his activity
not the LD micro conference, the one before, i listened the whole conference november 2nd. what he means without seeing new data, BPs not going to make any decisions.
Remember Ken said at conference, BPs are waiting for data
I wish i could have $10million dollars right now and buy half of the company!
Two reasons why no insider buying:
1. they knew another dilution is coming
2. in the middle of deal negotiation.
website is falling a part. Career page is unavailable
https://www.advaxis.com/about-us/?pagelink=careers
To raising money, KEN is a amateur compare to Dan. Another raise by Dan with Oncosec
OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share
https://finance.yahoo.com/news/oncosec-receives-7-million-investment-133000368.html
This is an exciting time for Advaxis as we prepare to initiate the first clinical trial with a drug candidate from our ADXS-HOT program. This drug candidate, ADXS-503, has been designed for the treatment of patients with NSCLC,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “With our increased strategic focus on neoantigen-based therapeutics, including the personalized, patient-specific approach of our ADXS-NEO program, already in a clinical trial, we anticipate having five neoantigen-based drug candidates in clinical evaluation by the end of 2019. Our next two ADXS-HOT drug candidates will focus on prostate and bladder cancers. These two tumor types, along with NSCLC, were prioritized based on our evaluation of a number of factors relating to each, including the unmet medical need, time and investment required to demonstrate meaningful clinical activity and immunological sensitivity,” concluded Mr. Berlin.
The Company plans to initiate a Phase 1/2 clinical trial that will seek to establish the safety, tolerability and effectiveness of ADXS-503 administered alone and in combination with a checkpoint inhibitor in approximately 50 patients with metastatic NSCLC in different lines of therapy, at up to 20 centers across the U.S.
J&J's Janssen Inks Deal With Korea’s Yuhan for NSCLC Drug Valued at up to $1.25 Billion
After drop Aduro deal, that's what they did. ADXS-HOT for NSCLC is worth at least $1 Billlion IMO
https://www.biospace.com/article/janssen-inks-deal-with-korea-s-yuhan-for-nsclc-drug-valued-at-up-to-1-25-billion/
no insiders buy filing today?
But OncoMed failed all clinical trials, Advaxis not, I think everything will turn around in 2019 with good positive data, or bad data and this company is over!
The company last year reported a series of clinical trial failures. One drug partnered with Celgene failed a mid-stage pancreatic cancer study, Bayer opted not to move forward with another program of cancer-fighting drugs, a drug in a GSK collaboration failed a mid-stage lung cancer trial and patients taking a drug in a Phase I study had such bad cases of diarrhea that the company stopped the program.
OncoMed, which once employed 122 people, had 56 employees at the end of last year and is expected to have $38 million in cash by the time the deal closes in first-half 2019. The combined company would have $115.5 million in cash as of the end of the third quarter — enough money to operate into 2020.
This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
https://www.bizjournals.com/sanfrancisco/news/2018/12/05/oncomed-mereo-cancer-omed-mph-celgene-celg.html?ana=yahoo&yptr=yahoo
With over 100 employees, phase 3 company, trading at $0.40 PS, look at LOXO , only 50 employees, 2015 was at $12.00 PS, now trading at $135.00 PS, what a difference! is it management or science?
Stock so cheap still no insider buying, something is cooking!
What's the reason no insiders buying? stock is very cheap at these prices.
you still think buyout is coming?
Hard to believe company Advaxis founded 2002 end up like this after 16 years in business.
Advaxis current ownership
https://www.marketscreener.com/ADVAXIS-INC-14609341/company/
loxo 2015 pps $11 2018 pps $138 wow!
Bristol-Myers Squibb shares decline on failed lung-cancer drug study
Come on Ken, make a deal with BMY!
https://www.marketwatch.com/story/bristol-myers-squibb-shares-decline-on-failed-lung-cancer-drug-study-2018-11-26?siteid=yhoof2&yptr=yahoo
Can you believe it each ADXS share cost less than two quarters right now. It is silly not to buy some at this price. I did it today. JMO
Just met one of my old classmate who works at a top mutual fund company,back in town for thanksgiving holiday. he said health care and biotechnology are going to be a great year in 2019. I told him that's what I'm thinking too. Happy thanksgiving!
Key AstraZeneca lung cancer treatment misses study goal
https://www.yahoo.com/news/astrazenecas-pivotal-lung-cancer-trial-fails-main-goal-073025263--finance.html